Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

PHAT

Phathom Pharmaceuticals, Inc. · NASDAQ

Performance

+4.17%

1W

+4.35%

1M

+62.75%

3M

+79.28%

6M

+97.15%

YTD

+126.42%

1Y

Profile

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Technical Analysis of PHAT 2024-11-06

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 43 suggests a neutral stance that may warrant caution. Overall, the Technical Score of 66 reinforces a generally positive outlook, though investors should remain aware of potential fluctuations indica...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of PHAT

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.